NVNO · enVVeno Medical Corp · Insider Trading

This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

This transaction was executed in multiple trades during the day at prices ranging from $11.5200 to $11.5450, inclusive. The weighted-average price is reported above. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were completed.

The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.

The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.

The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.

The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended . The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.

The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended . The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.

The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.

This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

This transaction was executed in multiple trades during the day at prices ranging from $0.3554 to $0.3573, inclusive. The weighted-average price is reported above. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were completed.

The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.

This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

This transaction was executed in multiple trades during the day at prices ranging from $0.8205 to $0.84, inclusive. The weighted-average price is reported above. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were completed.

The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended.

The stock options shall vest quarterly, over a three (3) year period, with a one (1) year cliff, subject to the reporting person's continued service with the Company.

The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2025 calendar year.

The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2025 calendar year.

The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2025 calendar year.

The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2027.

The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2027.

The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2025 calendar year.

The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2027.

The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Amended and Restated 2016 Omnibus Incentive Plan. The award is subject to time-based vesting and will vest in equal quarterly installments during the three calendar years through 2026. The portion of the stock options exercised in this transaction was fully vested and exercisable on the transaction date.

The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2024 calendar year.

The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2026.

The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2024 calendar year.

The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2024 calendar year.

The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2026.

The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2026.

The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2024 calendar year.

The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2026.

The common stock options were issued to the Reporting Person on November 30, 2022 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2023 calendar year.

The common stock options were issued to the Reporting Person on November 30, 2022 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2023 calendar year.

The common stock options were issued to the Reporting Person on November 30, 2022 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2023 calendar year.

The common stock options were issued to the Reporting Person on November 30, 2022 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2023 calendar year.

Each restricted stock unit ("RSU") converts into one share of common stock of enVVeno Medical Corporation.

On September 13, 2019, the reporting person was granted 3,125 RSUs (78,125 RSUs pre one-for-twenty five (1:25) reverse stock split that was effected in November 2020), subject to vesting and settlement as described in the person's Form 4, as filed on October 10, 2020. The vesting and settlement of the RSUs occurred in September 2020, 2021 and 2022.

Each restricted stock unit ("RSU") converts into one share of common stock of enVVeno Medical Corporation.

On September 13, 2019, the reporting person was granted 3,125 RSUs (78,125 RSUs pre one-for-twenty five (1:25) reverse stock split that was effected in November 2020), subject to vesting and settlement as described in the person's Form 4, as filed on October 10, 2020. The vesting and settlement of the RSUs occurred in September 2020, 2021 and 2022.

Each restricted stock unit ("RSU") converts into one share of common stock of enVVeno Medical Corporation.

Each restricted stock unit ("RSU") converts into one share of common stock of enVVeno Medical Corporation.

The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2022 calendar year.

The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2022 calendar year.

The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2022 calendar year.